A new drug for an old concept: aptamer to von Willebrand factor for prevention of arterial and microvascular thrombosis

被引：4
|
作者：
Veyradier, Agnes [1 ,2 ]
机构：
[1] Hosp Lariboisiere, AP HP Nord, French Natl Reference Ctr Thrombot Microangiopath, Hematol Dept, Paris, France
[2] Paris Univ, EA3548 St Louis Res Inst, Paris, France
来源：
HAEMATOLOGICA | 2020年 / 105卷 / 11期
关键词：
THROMBOCYTOPENIC PURPURA; PLATELET-FUNCTION; FACTOR A1-DOMAIN; DNA APTAMER; ARC1779; INHIBITION; EFFICACY; SAFETY; VIVO;
D O I：
10.3324/haematol.2020.261081
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2512 / 2515
页数：4
相关论文
共 28 条
  • [1] Thrombosis and von Willebrand Factor
    Shahidi, Minoo
    THROMBOSIS AND EMBOLISM: FROM RESEARCH TO CLINICAL PRACTICE, VOL 1, 2017, 906 : 285 - 306
  • [2] Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis
    Bettoni, Serena
    Galbusera, Miriam
    Gastoldi, Sara
    Donadelli, Roberta
    Tentori, Chiara
    Sparta, Giuseppina
    Bresin, Elena
    Mele, Caterina
    Alberti, Marta
    Tortajada, Agustin
    Yebenes, Hugo
    Remuzzi, Giuseppe
    Noris, Marina
    JOURNAL OF IMMUNOLOGY, 2017, 199 (03) : 1021 - 1040
  • [3] An Anti-von Willebrand Factor Aptamer Reduces Platelet Adhesion Among Patients Receiving Aspirin and Clopidogrel in an Ex Vivo Shear-Induced Arterial Thrombosis
    Arzamendi, Dabit
    Dandachli, Firas
    Theoret, Jean-Francois
    Ducrocq, Gregory
    Chan, Mark
    Mourad, Walid
    Gilbert, James C.
    Schaub, Robert G.
    Tanguay, Jean-Francois
    Merhi, Yahye
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2011, 17 (06) : E70 - E78
  • [4] Low-density lipoprotein promotes microvascular thrombosis by enhancing von Willebrand factor self-association
    Chung, Dominic W.
    Platten, Kimsey
    Ozawa, Koya
    Adili, Reheman
    Pamir, Nathalie
    Nussdorfer, Forrest
    John, Alexander St.
    Ling, Minhua
    Le, Jennie
    Harris, Jeff
    Rhoads, Nicole
    Wang, Yi
    Fu, Xiaoyun
    Chen, Junmei
    Fazio, Sergio
    Lindner, Jonathan R.
    Lopez, Jose A.
    BLOOD, 2023, 142 (13) : 1156 - 1166
  • [5] Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
    Lenting, Peter J.
    Denis, Cecile V.
    Wohner, Nikolett
    CURRENT VASCULAR PHARMACOLOGY, 2013, 11 (04) : 448 - 456
  • [6] The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer
    Zhu, Shuhao
    Gilbert, James C.
    Hatala, Paul
    Harvey, Warren
    Liang, Zicai
    Gao, Shan
    Kang, Daiwu
    Jilma, Bernd
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (05) : 1113 - 1123
  • [7] Potent and rapid reversal of the von Willebrand factor inhibitor aptamer BT200
    Zhu, Shuhao
    Gilbert, James C.
    Liang, Zicai
    Kang, Daiwu
    Li, Ming
    Tarantino, Paul M.
    Jilma, Bernd
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1695 - 1704
  • [8] von Willebrand Factor, Shear Stress, and ADAMTS13 in Hemostasis and Thrombosis
    Tsai, Han-Mou
    ASAIO JOURNAL, 2012, 58 (02) : 163 - 169
  • [9] Time to think outside the box? Proposals for a new approach to future pharmacokinetic studies of von Willebrand factor concentrates in people with von Willebrand disease
    Favaloro, Emmanuel J.
    Kershaw, Geoff
    McLachlan, Andrew J.
    Lloyd, John
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (08) : 745 - 758
  • [10] A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease
    Jilma, Bernd
    Paulinska, Petra
    Jilma-Stohlawetz, Petra
    Gilbert, James C.
    Hutabarat, Renta
    Knoebl, Paul
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (03) : 563 - 570
123